As Aurora Cannabis (TSE: ACB) continues its efforts to be a major global entity in the cannabis space, it has added another successful deal to its growing list. According to an announcement by the company today, it will soon be distributing cannabidiol (CBD) drops in Ireland after receiving approval from Ireland’s Medical Cannabis Access Programme (MCAP) and being recognized by the Irish Minister of Health to allow for their importation, supply and prescription.
MCAP just took effect this past June and will be in place for five years, when it will be evaluated for further implementation. The availability of the CBD drops will allow healthcare providers to prescribe them for a number of medical conditions, including spasticity associated with multiple sclerosis, intractable nausea and vomiting associated with chemotherapy and severe, refractory (treatment-resistant) epilepsy.
Aurora’s chief product officer, Dr. Shane Morris, explains, Aurora is pleased to be able to assist patients who are seeking treatment with high-quality EU-GMP (good manufacturing practice) certified pharmaceutical-grade medical cannabis in Ireland. We are very proud to be one of the first approved suppliers of medical cannabis under the MCAP. We want to acknowledge the efforts made by many people, especially the patients and doctors who have campaigned for access to these medicines. We look forward to more of Aurora’s high-quality medicines being approved, so that more patients can benefit from the MCAP in Ireland. We will continue to work closely with all parties and state agencies to facilitate further availability.”
Only two products have been approved by the Minister of Health, Simon Harris, and the MCAP program. The addition of Aurora’s High CBD Oil Drops goes a long way in showing the value of the company’s products and its continued efforts to be a responsible leader in the cannabis industry.